company background image
CRBU

Caribou Biosciences NasdaqGS:CRBU Stock Report

Last Price

US$9.67

Market Cap

US$591.3m

7D

32.6%

1Y

n/a

Updated

17 May, 2022

Data

Company Financials +
CRBU fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CRBU Stock Overview

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally.

Caribou Biosciences Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Caribou Biosciences
Historical stock prices
Current Share PriceUS$9.67
52 Week HighUS$32.65
52 Week LowUS$6.41
Beta0
1 Month Change18.80%
3 Month Change-14.95%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-40.75%

Recent News & Updates

May 13
Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

It's been a good week for Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders, because the company has just released...

Apr 26

Caribou Biosciences: Selling Close To Cash Balance

Today, we put developmental biotech company Caribou Biosciences in the spotlight for the first time. This nascent gene editing concern has fallen deep in 'Busted IPO' as any enthusiasm on the biotech sector has faded substantially in recent quarters. The stock now sells for near the cash on its balance sheet. Time to buy the dip? A full investment analysis follows in the paragraphs below.

Shareholder Returns

CRBUUS BiotechsUS Market
7D32.6%4.8%0.7%
1Yn/a-22.0%-10.8%

Return vs Industry: Insufficient data to determine how CRBU performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how CRBU performed against the US Market.

Price Volatility

Is CRBU's price volatile compared to industry and market?
CRBU volatility
CRBU Average Weekly Movement12.7%
Biotechs Industry Average Movement12.3%
Market Average Movement7.8%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market2.9%

Stable Share Price: CRBU is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: CRBU's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201167Rachel Haurwitzhttps://cariboubio.com

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors.

Caribou Biosciences Fundamentals Summary

How do Caribou Biosciences's earnings and revenue compare to its market cap?
CRBU fundamental statistics
Market CapUS$591.27m
Earnings (TTM)-US$72.85m
Revenue (TTM)US$10.68m

55.0x

P/S Ratio

-8.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CRBU income statement (TTM)
RevenueUS$10.68m
Cost of RevenueUS$56.01m
Gross Profit-US$45.34m
Other ExpensesUS$27.51m
Earnings-US$72.85m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.20
Gross Margin-424.67%
Net Profit Margin-682.39%
Debt/Equity Ratio0%

How did CRBU perform over the long term?

See historical performance and comparison

Valuation

Is Caribou Biosciences undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


1.58x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CRBU's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CRBU's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: CRBU is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CRBU is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CRBU's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CRBU is overvalued based on its PB Ratio (1.6x) compared to the US Biotechs industry average (1.4x).


Future Growth

How is Caribou Biosciences forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-25.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRBU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CRBU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CRBU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CRBU's revenue (32.4% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: CRBU's revenue (32.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CRBU is forecast to be unprofitable in 3 years.


Past Performance

How has Caribou Biosciences performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-93.4%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: CRBU is currently unprofitable.

Growing Profit Margin: CRBU is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if CRBU's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare CRBU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CRBU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: CRBU has a negative Return on Equity (-19.59%), as it is currently unprofitable.


Financial Health

How is Caribou Biosciences's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CRBU's short term assets ($368.0M) exceed its short term liabilities ($26.7M).

Long Term Liabilities: CRBU's short term assets ($368.0M) exceed its long term liabilities ($47.5M).


Debt to Equity History and Analysis

Debt Level: CRBU is debt free.

Reducing Debt: CRBU had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CRBU has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CRBU has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 35.9% each year.


Dividend

What is Caribou Biosciences's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CRBU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CRBU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CRBU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRBU's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CRBU has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Rachel Haurwitz (35 yo)

10.58yrs

Tenure

US$6,249,919

Compensation

Dr. Rachel E. Haurwitz, Ph D., has been the President and Chief Executive Officer at Caribou Biosciences, Inc. since October 2011. She serves as an Independent Director at Seer, Inc since November 08, 2021...


CEO Compensation Analysis

Compensation vs Market: Rachel's total compensation ($USD6.25M) is above average for companies of similar size in the US market ($USD2.62M).

Compensation vs Earnings: Rachel's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CRBU's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: CRBU's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: CRBU only recently listed within the past 12 months.


Top Shareholders

Company Information

Caribou Biosciences, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Caribou Biosciences, Inc.
  • Ticker: CRBU
  • Exchange: NasdaqGS
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$591.271m
  • Shares outstanding: 60.71m
  • Website: https://cariboubio.com

Number of Employees


Location

  • Caribou Biosciences, Inc.
  • 2929 7th Street
  • Suite 105
  • Berkeley
  • California
  • 94710
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/17 00:00
End of Day Share Price2022/05/17 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.